AU2011331992A1 - Stable preserved compositions of interferon-beta - Google Patents
Stable preserved compositions of interferon-beta Download PDFInfo
- Publication number
- AU2011331992A1 AU2011331992A1 AU2011331992A AU2011331992A AU2011331992A1 AU 2011331992 A1 AU2011331992 A1 AU 2011331992A1 AU 2011331992 A AU2011331992 A AU 2011331992A AU 2011331992 A AU2011331992 A AU 2011331992A AU 2011331992 A1 AU2011331992 A1 AU 2011331992A1
- Authority
- AU
- Australia
- Prior art keywords
- composition
- interferon
- beta
- concentration
- interferon beta
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41629110P | 2010-11-22 | 2010-11-22 | |
| US61/416,291 | 2010-11-22 | ||
| PCT/US2011/061759 WO2012071366A1 (en) | 2010-11-22 | 2011-11-22 | Stable preserved compositions if interferon-beta |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2011331992A1 true AU2011331992A1 (en) | 2013-06-13 |
Family
ID=46146183
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2011331992A Abandoned AU2011331992A1 (en) | 2010-11-22 | 2011-11-22 | Stable preserved compositions of interferon-beta |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20120269770A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP2643469A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2013543872A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2011331992A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2818671A1 (cg-RX-API-DMAC7.html) |
| MX (1) | MX2013005699A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2012071366A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014130811A1 (en) * | 2013-02-22 | 2014-08-28 | Biogen Idec Ma Inc | Interferon beta formulation |
| WO2016163764A2 (ko) * | 2015-04-07 | 2016-10-13 | 에이비온 주식회사 | 인터페론 베타 변이체의 안정화 제제 |
| FI126979B (en) * | 2016-02-29 | 2017-09-15 | Faron Pharmaceuticals Oy | Lyophilized pharmaceutical formulation and its use |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1272252B (it) * | 1994-05-16 | 1997-06-16 | Applied Research Systems | Formulazioni liquide di interferone beta |
| US6887462B2 (en) * | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| US7731948B2 (en) * | 2004-06-01 | 2010-06-08 | Ares Trading S.A. | Stabilized interferon liquid formulations |
| RS52417B (sr) * | 2007-12-20 | 2013-02-28 | Merck Serono S.A. | Formulacije peg-interferona-beta |
-
2011
- 2011-11-21 US US13/301,354 patent/US20120269770A1/en not_active Abandoned
- 2011-11-22 WO PCT/US2011/061759 patent/WO2012071366A1/en not_active Ceased
- 2011-11-22 EP EP11843556.9A patent/EP2643469A1/en not_active Withdrawn
- 2011-11-22 MX MX2013005699A patent/MX2013005699A/es not_active Application Discontinuation
- 2011-11-22 JP JP2013540105A patent/JP2013543872A/ja active Pending
- 2011-11-22 AU AU2011331992A patent/AU2011331992A1/en not_active Abandoned
- 2011-11-22 CA CA2818671A patent/CA2818671A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20120269770A1 (en) | 2012-10-25 |
| MX2013005699A (es) | 2013-08-27 |
| CA2818671A1 (en) | 2012-05-31 |
| WO2012071366A8 (en) | 2013-06-20 |
| JP2013543872A (ja) | 2013-12-09 |
| EP2643469A1 (en) | 2013-10-02 |
| WO2012071366A1 (en) | 2012-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5346065B2 (ja) | Hsaを含まない安定なインターフェロン液体製剤 | |
| EP1093818B9 (en) | Powdery preparation for mucosal administration containing polymeric medicine | |
| CA2403962C (en) | Powdery preparation for transmucosal administration comprising a medicine of high molecular weight and exhibiting an improved storage stability | |
| JP4988562B2 (ja) | 安定化したインターフェロン液体製剤 | |
| US9138403B2 (en) | PEG-interferon-beta formulations | |
| EP2911685A2 (en) | Stable pharmaceutical composition of peginterferon alpha-2b | |
| ES2374530T3 (es) | Formulaciones líquidas de interferón estabilizado. | |
| US20120269770A1 (en) | Stable Preserved Compositions of Interferon-Beta | |
| WO2014130811A1 (en) | Interferon beta formulation | |
| HK1088847B (en) | Human serum albumin-free stabilized interferon liquid formulations | |
| HK1102563B (en) | Stabilized interferon liquid formulations |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |